These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 38194219)

  • 21. Thyroid eye disease or Graves' orbitopathy: What name to use, and why it matters.
    Wagner LH; Bradley EA; Tooley AA; Ren Y; Rachmasari KN; Stan MN
    Front Endocrinol (Lausanne); 2022; 13():1083886. PubMed ID: 36518254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Corticosteroids in Moderate-To-Severe Graves' Ophthalmopathy: Oral or Intravenous Therapy?
    Penta L; Muzi G; Cofini M; Leonardi A; Lanciotti L; Esposito S
    Int J Environ Res Public Health; 2019 Jan; 16(1):. PubMed ID: 30626069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of thyroid eye disease in Graves' disease: A meta-analysis and systematic review.
    Chin YH; Ng CH; Lee MH; Koh JWH; Kiew J; Yang SP; Sundar G; Khoo CM
    Clin Endocrinol (Oxf); 2020 Oct; 93(4):363-374. PubMed ID: 32691849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Comparison of Observational Studies on Subfoveal Choroidal Thickness Measured with OCT according to the Level of Thyroid Eye Disease Activity-Systematic Review and Meta-Analysis.
    Kowalik-Jagodzińska M; Sobol M; Turno-Kręcicka A
    J Clin Med; 2023 Jul; 12(14):. PubMed ID: 37510836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypo vs. hyperthyroid eye disease: is there any difference?
    Eshraghi B; Pourazizi M; Abbasi M; Mohammadbeigy I
    BMC Ophthalmol; 2023 Feb; 23(1):58. PubMed ID: 36765316
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thyroid-associated ophthalmopathy in juvenile Graves' disease--clinical, endocrine and therapeutic aspects.
    Krassas GE; Gogakos A
    J Pediatr Endocrinol Metab; 2006 Oct; 19(10):1193-206. PubMed ID: 17172081
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rituximab for thyroid-associated ophthalmopathy.
    Kang S; Hamed Azzam S; Minakaran N; Ezra DG
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD009226. PubMed ID: 35709102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cigarette smoking and thyroid eye disease: a systematic review.
    Thornton J; Kelly SP; Harrison RA; Edwards R
    Eye (Lond); 2007 Sep; 21(9):1135-45. PubMed ID: 16980921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease.
    Ayabe R; Rootman DB; Hwang CJ; Ben-Artzi A; Goldberg R
    Ophthalmic Plast Reconstr Surg; 2014; 30(5):415-9. PubMed ID: 24978425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic Utility of a New Assay for Thyroid Stimulating Immunoglobulins in Graves' Disease and Thyroid Eye Disease.
    Stan MN; Algeciras-Schimnich A; Murthy V; Thapa P; Araki N
    Thyroid; 2022 Feb; 32(2):170-176. PubMed ID: 34714163
    [No Abstract]   [Full Text] [Related]  

  • 31. Early use of steroid-sparing agents in the inactivation of moderate-to-severe active thyroid eye disease: a step-down approach.
    Sipkova Z; Insull EA; David J; Turner HE; Keren S; Norris JH
    Clin Endocrinol (Oxf); 2018 Dec; 89(6):834-839. PubMed ID: 30103255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug safety in thyroid eye disease - a systematic review.
    Wolf J; Mitka KI; Hubalewska-Dydejczyk A; Krämer I; Kahaly GJ
    Expert Opin Drug Saf; 2022 Jul; 21(7):881-912. PubMed ID: 35447047
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies.
    Winn BJ; Kersten RC
    Ophthalmology; 2021 Nov; 128(11):1627-1651. PubMed ID: 33930408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Statin reduces orbitopathy risk in patients with Graves' disease by modulating apoptosis and autophagy activities.
    Bifulco M; Ciaglia E
    Endocrine; 2016 Sep; 53(3):649-50. PubMed ID: 26438397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The "Quiet TED"-A Special Subgroup of Thyroid Eye Disease.
    Iñiguez-Ariza NM; Sharma A; Garrity JA; Stan MN
    Ophthalmic Plast Reconstr Surg; 2021 Nov-Dec 01; 37(6):551-555. PubMed ID: 33782324
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum Vitamin D Deficiency Is an Independent Risk Factor for Thyroid Eye Disease.
    Heisel CJ; Riddering AL; Andrews CA; Kahana A
    Ophthalmic Plast Reconstr Surg; 2020; 36(1):17-20. PubMed ID: 31568022
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An Appraisal of the Preventive Effect of Statins on the Development of Graves' Ophthalmopathy: A Hospital-Based Cohort Study.
    Hsu GC; Shih SR; Chang FY; Liao SL; Wei YH
    Ophthalmol Ther; 2024 Jun; 13(6):1499-1511. PubMed ID: 38581604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radioiodine therapy versus antithyroid medications for Graves' disease.
    Ma C; Xie J; Wang H; Li J; Chen S
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD010094. PubMed ID: 26891370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential involvement of the bone marrow in experimental Graves' disease and thyroid eye disease.
    Gulbins A; Horstmann M; Keitsch S; Soddemann M; Wilker B; Wilson GC; Zeidan R; Hammer GD; Daser A; Bechrakis NE; Görtz GE; Eckstein A
    Front Endocrinol (Lausanne); 2023; 14():1252727. PubMed ID: 37810891
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.